Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Patient Profile 2: Patient with de novo AML and IDH2 Mutation

June 16th 2022

Drs Richard Stone and Eunice Wang review the clinical profile of a 67-year-old man with newly diagnosed acute myeloid leukemia (AML) and an IDH2 mutation.

Ibrutinib Plus Venetoclax Produces High MRD Negativity Rate in Previously Untreated CLL

June 15th 2022

The addition of venetoclax to ibrutinib resulted in a high rate of minimal residual disease negativity in the blood and marrow of patients with previously untreated chronic lymphocytic leukemia.

FDA Panel Gives Beti-Cel Unanimous Support of Benefit in β-thalassemia

June 14th 2022

The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted unanimously in favor of the benefit of betibeglogene autotemcel for the treatment of transfusion-dependent β-thalassemia in adult and pediatric patients with a non–β0/β0 genotype.

RG6234 Is Highly Active in Relapsed/Refractory Multiple Myeloma

June 13th 2022

RG6234, a novel T-cell engaging bispecific antibody with a 2:1 configuration, induced high response rates and early evidence of durability for patients with relapsed/refractory multiple myeloma.

Dr. Gisslinger on EFS Rates With Ropeginterferon Alfa-2b in Polycythemia Vera

June 13th 2022

Heinz Gisslinger, MD, discusses the 6-year event-free survival data from the phase 3 PROUD-PV and CONTI-PV trials.

Dr. Short on Ponatinib and Blinatumomab in Philadelphia Chromosome–Positive ALL

June 13th 2022

Nicholas J. Short, MD, discusses updated results from a single-arm phase 2 study investigating ponatinib plus blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

REGN5458 Elicits Early, Sustainable Responses in Heavily Pretreated Multiple Myeloma

June 13th 2022

The bispecific antibody REGN5458 elicited rapid responses that were further characterized by their depth, durability, and low incidence of cytokine release syndrome in patients with relapsed/refractory multiple myeloma.

Ropeginterferon Alfa-2b Demonstrates Long-Term QOL Improvements in Polycythemia Vera

June 13th 2022

Treatment with ropeginterferon alfa-2b-njft induced low symptom burden and low phlebotomy requirement compared with best available treatment in patients with polycythemia vera, according to long-term data from the phase 3 PROUD-PV and CONTINUATION-PV trials.

Bezuclastinib Demonstrates Early Promise in Advanced Systemic Mastocytosis

June 13th 2022

Bezuclastinib showcased early signs of clinical activity in that it resulted in a meaningful reduction in serum tryptase levels, as well as reductions in mast cell burden and KIT D816V variant allele frequency, in adult patients with advanced systemic mastocytosis.

Talquetamab Plus Daratumumab Generates High Response Rate in CD38-Refractory Myeloma

June 12th 2022

The combination of talquetamab and daratumumab led to early onset and durable responses that deepened over time in patients with heavily pretreated multiple myeloma, most of whom were anti-CD38 refractory, according to findings from the phase 1b TRIMM-2 study.

Frontline Subcutaneous Epcoritamab Plus R-CHOP Elicits ORR of 100% in High-Risk DLBCL

June 12th 2022

The combination of epcoritamab and R-CHOP produced high overall response rates and complete metabolic response rates with a manageable toxicity profile in patients with diffuse large B-cell lymphoma.

BRUIN CLL-313 Trial To Evaluate Pirtobrutinib in Untreated CLL/SLL

June 12th 2022

The phase 3 BRUIN CLL-313 trial is currently recruiting patients with treatment naïve chronic lymphocytic leukemia or small lymphocytic lymphoma to evaluate the efficacy and safety of pirtobrutinib monotherapy vs bendamustine plus rituximab.

Zandelisib Elicits High Response in Relapsed/Refractory Follicular Lymphoma

June 12th 2022

Zandelisib, a potent and selective oral PI3Kδ inhibitor, elicited a high overall response rate as a single agent in heavily pretreated patients with relapsed or refractory follicular lymphoma, according to data from the phase 2 TIDAL trial.

Obinutuzumab/Chemo Maintains Superior PFS in Untreated Follicular Lymphoma at 8 Years

June 12th 2022

The combination of obinutuzumab plus chemotherapy delivered superior long-term progression-free survival benefit for patients with treatment-naïve follicular lymphoma.

R-CODOX-M/R-IVAC Fails to Establish Superior Efficacy Over DA-EPOCH-R in High-Risk Burkitt Lymphoma

June 12th 2022

Treatment with the R-CODOX-M and R-IVAC regimens elicited similar efficacy to dose-adjusted infused DA-EPOCH-R in patients with newly diagnosed, high-risk Burkitt lymphoma.

Long-term Treatment With Luspatercept Reduces Transfusion Dependence Associated With β-Thalassemia

June 12th 2022

The longest duration of reduction in red blood cell transfusion dependence was reported among patients with β-thalassemia who received continued treatment with luspatercept-aamt in the updated data from the phase 3 BELIEVE trial.

Quizartinib Triplet Shows Activity in Heavily Pretreated, FLT3-ITD–Mutated AML

June 11th 2022

The triplet combination regimen comprised of quizartinib, decitabine, and venetoclax elicited encouraging responses in heavily pretreated patients with relapsed/refractory FLT3-ITD–mutated acute myeloid leukemia who were previously exposed to a FLT3 inhibitor.

Epcoritamab Elicits Impressive Responses in Relapsed/Refractory LBCL

June 11th 2022

The first-in-class, subcutaneously administered T-cell–engaging bispecific antibody epcoritamab demonstrated deep and durable responses in patients with relapsed/refractory large B-cell lymphoma.

Dr. Yilmaz on the Benefit of Quizartinib Triplet in AML

June 11th 2022

Musa Yilmaz, MD, discusses composite complete remission and bone marrow transplant rates observed in a phase 1/2 trial in patients with FLT3-ITD–mutated acute myeloid leukemia.

Decitabine Displays Comparable Outcomes, Improved Safety to Induction Chemotherapy in Older AML

June 11th 2022

Decitabine demonstrated a comparable overall survival and rate of hematopoietic stem cell transplant in addition to a lower incidence of adverse effects vs induction chemotherapy with daunorubicin and cytarabine in older patients at least 60 years of age with acute myeloid leukemia.